Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference release_fysh5xmjynf3vmk7vz7uizablq

by Somayya Noori, Christie P. M. Verkleij, Marina Zajec, Pieter Langerhorst, Patricia W. C. Bosman, Yolanda B. de Rijke, Sonja Zweegman, Martijn VanDuijn, Theo Luider, Niels W. C. J. van de Donk, Joannes F. M. Jacobs

Published in Clinical Chemistry and Laboratory Medicine by Walter de Gruyter GmbH.



<jats:title>Abstract</jats:title> <jats:sec id="j_cclm-2021-0399_abs_001_w2aab3b7b1b1b6b1aab1c14b1Aa"> <jats:title>Objectives</jats:title> The therapeutic monoclonal antibody (t-mAb) daratumumab, used to treat multiple myeloma (MM) patients, interferes with routine, electrophoretic based M-protein diagnostics. Electrophoretic response assessment becomes increasingly difficult when multiple t-mAbs are combined for use in a single patient. This is the first study to address the analytical challenges of M-protein monitoring when multiple t-mAbs are combined. </jats:sec> <jats:sec id="j_cclm-2021-0399_abs_002_w2aab3b7b1b1b6b1aab1c14b2Aa"> <jats:title>Methods</jats:title> In this proof-of-principle study we evaluate two different methods to monitor M-protein responses in three MM patients, who receive both daratumumab and nivolumab. The double hydrashift assay aims to resolve t-mAb interference on immunofixation. The MS-MRD (mass spectrometry minimal residual disease) assay measures clonotypic peptides to quantitate both M-protein and t-mAb concentrations. </jats:sec> <jats:sec id="j_cclm-2021-0399_abs_003_w2aab3b7b1b1b6b1aab1c14b3Aa"> <jats:title>Results</jats:title> After exposure to daratumumab and nivolumab, both t-mAbs become visible on immunofixation electrophoresis (IFE) as two IgG-kappa bands that migrate close to each other at the cathodal end of the γ-region. In case the M-protein co-migrates with these t-mAbs, the observed interference was completely abolished with the double IFE hydrashift assay. In all three patients the MS-MRD assay was also able to distinguish the M-protein from the t-mAbs. Additional advantage of the MS-MRD assay is that this multiplex assay is more sensitive and allows quantitative M-protein-, daratumumab- and nivolumab-monitoring. </jats:sec> <jats:sec id="j_cclm-2021-0399_abs_004_w2aab3b7b1b1b6b1aab1c14b4Aa"> <jats:title>Conclusions</jats:title> Daratumumab and nivolumab interfere with electrophoretic M-protein diagnostics. However, the M-protein can be distinguished from both t-mAbs by use of a double hydrashift assay. The MS-MRD assay provides an alternative method that allows sensitive and simultaneous quantitative monitoring of both the M-protein and t-mAbs. </jats:sec>
In application/xml+jats format

Archived Files and Locations

application/pdf  659.0 kB
file_ucedqsom3benzdkgw45i2eaw5i (webarchive) (publisher)
Read Archived PDF
Type  article-journal
Stage   published
Date   2021-08-16
Language   en ?
Container Metadata
Not in DOAJ
In Keepers Registery
ISSN-L:  1434-6621
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 729cb5c7-2511-444c-afee-5fb3a71d08a0